2025 2nd Quarter Financial Results

For Healthier GENerations

Brand **Timeline**



A View to GEN

600+ employees

7 different countries
9 offices

10 different countries
22 global partner

10 different countries
13 business partner abroad

4 Affiliated Companies
7 Subsidiaries

Turkish Medicine Industry
Fastest Growing Company
(Since 2014)

15 Imported products
7 different country sales

29 NPP products
2 different country sales

29 Produced products
8 different country sales

Business Model

NPP Drugs

Drugs which prescribed by the doctors for the treatment of diseases and import permission is given by the Republic of Türkiye Ministry of Health but not registered in Türkiye and import can be imported trough Turkish Pharmacists Association (TEB), Türkiye Social Security Agency (SGK) and USHAŞ (Internations Health Services Inc.). Name of this import of drugs and delivery of the patients model is NPP (Named Patient Program) Drugs in this category and their producers represented in our country with exclusive distributorship agreement. Main difference between registered imported drugs and these drugs is sales of these drugs are not made in pharmaceutical warehouse but made in TEB, SGK and USHAŞ and sales price is determined in foreign currency.

Registered Imported Drugs

Registered imported drugs refer to the product portfolio for which GEN holds exclusive rights under distributorship agreements with foreign manufacturers. These drugs are registered with the Republic of Türkiye Ministry of Health, and the registrations are made on behalf of our company. All of these drugs fall under the reimbursement scheme. The registration process is detailed and may take up to two years after the application. The sales prices of these drugs are determined by the health authorities.

Branded Generic Drugs

In addition to original drugs, it has activities on development and sales of drugs which suitable for its portfolio and patent term expired.

Strong Sales Performance*

In 2025/Q2 **all-times record by quarterly sales volume** TL 4,1 Bn

NPP Drug sales reached TL 1,7 Bn

Compared to the same period of 2024

23% growth

In the first half of 2025 31% growth

Compared to the same period of 2024

*These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.

Q2 Sales by Years (TL / '000)

2024 – 2025 First 6 Months Sales (TL / '000)



Drug Sales*

In Production Registered Drugs sales for the first 6 months of 2025, compared to the same period of 2024 **48% increase**

In Imported Registered Drugs sales for the first half of 2025 compared to the same period of 2024 **36% increase**

In NPP Drugs sales for the first half of 2025 Compared to the same period of 2024 **22% increase**

Activity Fields	22/Q1	22/Q2	22/Q3	22/Q4	23/Q1	23/Q2	23/Q3	23/Q4	24/Q1	24/Q2	24/Q3	24/Q4	25/Q1	25/Q2
Exported Drugs	57	81	80	26	96	60	45	120	209	127	92	182	291	226
Imported Registerd Drugs	303	299	284	351	606	647	1.079	1.493	1.346	1.526	1.257	1.310	1.852	2.060
NPP Drugs	830	1.309	916	724	181	336	1.134	579	1.293	1.280	2.149	1.494	1.411	1.742
Production Registered Drugs	12	18	16	26	32	36	46	65	107	81	117	126	163	117
Total	**1.202**	**1.707**	**1.296**	**1.127**	**915**	**1.079**	**2.304**	**2.257**	**2.955**	**3.014**	**3.615**	**3.112**	**3.717**	**4.145**

Sales (TL)



Sales Distribution 2025/6M (%)



*These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.

Drug Sales Volume

Total number of boxes sold in the 2nd quarter of 2025

1.544.148

Compared to the same period in 2024, the total number of boxes sold in the 2nd quarter of 2025

%108 increase

Compared to the same period in 2024, drug sales in terms of boxes in the first 6 months of 2025

%25 increase

Q2 Sales by Years (Boxes – '000)



2025 / 6M Sales (Boxes – '000)



Export*

Compared to the same period of 2024
In total Export volume in 2025/Q2

%77 increase

Compared to the same period in 2024
Total Export in the first 6 months of 2025

%54 increase

Compared to the same period in 2024 In the first 6 months of 2025, export drugs sales in terms of boxes

%34 increase

Exports to 7 different countries

* These values are calculated based on the invoice amounts for the products sold by the company, and TAS 29 Financial Reporting Standards in High Inflation Economies has not been applied.

Export by Country

Ülke	TL
Azerbaijan	132.055.282
Kazakhstan	40.719.161
Uzbekistan	8.525.451
Russia	43.108.199
Others**	1.921.354
Total	**226.329.447**

**Albania ve Bosnia and Herzegovina

Distribution of Export 2025/Q2



Profitability (According to TAS 29)

Consolidated Gross Profit in 2025/Q2

893 mn TL

Compared to the 2nd Quarter of 2024 in EBITDA

Turn to Profit

Compared to the 2nd quarter of 2024 in Net Profit

Turn to Profit

Compared to the 2nd quarter of 2024 in Operating Profit

%9,9 increase

Profitability

Profit Margins (According to TAS 29)

Compared to the same period in 2024, in 2025/Q2 :

in Net Profit Margin

1,81% **Net Profit Margin**

1,73% **EBITDA Margin**

In Operating Profit Margin

0,7 **base point increase**

Profit Margins



Balance Sheet (According to TAS 29)

Equities

TL 8,9 Bn

Current Ratio

1,30

Assets

16+ Bn TL

Financial Leverage*

0,21x

**Total Financial Debts/Equities*

Balance Sheet

Assets & Liabilities	30.06.2025	31.12.2024
Total Current Assets	8.293.699.347	6.762.131.585
Total Fixed Assets	7.963.583.519	7.601.167.171
Total Assets	16.257.282.866	14.363.298.756
Total Short Term Liabilities	6.390.286.161	4.893.737.643
Total Long Term Liabilities	943.704.645	943.417.527
Total Liabilities	7.333.990.806	5.837.155.170
Total Current Assets	8.923.292.060	8.526.143.586
Current Raito	1,30	1,38

2025 Expectations (Non-TAS 29 Effect)

	Price Determination Report	Planned
Sales	7.151.006.771	>17,50 mr TL
Gross Profit	1.470.704.605	>4,20 mr TL
Operating Profit	1.080.259.478	>3,15 mr TL
EBITDA	1.154.020.937	> 3,32 mr TL
Gross Profit Margin	20,56%	>24%
Operating Profit Margin	15,10%	>18%
EBITDA Margin	16,13%	>19%



2025 Expectations (TAS 29 Applied)

	Price Determination Report	Planned
Sales	7.151.006.771	>22,75 mr TL
Gross Profit	1.470.704.605	>5,34 mr TL
Operating Profit	1.080.259.478	>1,93 mr TL
EBITDA	1.154.020.937	> 2,50 mr TL
Gross Profit Margin	20,56%	23,50%
Operating Profit Margin	15,10%	8,50%
EBITDA Margin	16,13%	11,00%

2025 Realizations (Non-TAS 29 Effect)

	2025	Planned	Coverage Rate
Sales	8.378.744.586	>22.750.000.000	36,83%
Gross Profit	**1.771.598.168**	**>5.340.000.000**	**33,17%**
Operational Profit	913.775.607	>1.930.000.000	47,34%
EBITDA	**557.862.785**	**>2.500.000.000**	**22,31%**
Gross Profit Margin	21,47%	23,50%	
Operating Profit Margin	**10,91%**	**8,50%**	
EBITDA Margin	6,66%	11,00%	

Income Statement (According to Turkish Tax Regulations)

TL	30.06.2025
Net Sales	7.897.054.795
Gross Profit	1.827.890.012
Operating Profit	746.336.296
EBITDA	990.981.580
Net Profit	855.272.144

* These are data in Turkish Lira for the period 01.01.2025 - 30.06.2025 prepared in accordance with the Turkish Tax Regulations.

Growing Abroad Network

An exclusive distributorship agreement was signed with UK-based Unikeris Limited for the import and supply of the drug **REVCOVI®** to Türkiye.

First Drug Producer in Azerbaijan

- **First Local Drug Producer** of Azerbaijan
- **USD 900 mn** drug market
- **66% GEN** Shareholder
- **USD 35 mn** Investment
- **2 years** project term
- **30%** equity financing
- **Incentives** provided by Azerbaijan State

Research and Development Activities

TL 44 mn
R&D Investments in 2025/Q2

34
Continuing R&D Project

14
Number of new projects planned for commercialization facility under construction in Azerbaijan

2
Technology Focused Industrial Move Projects

40+
R&D Team

APPROVED

Accredited R&D Center

Drug Portfolio

In the first 6 months of 2025,

13 products were licensed in Türkiye

2 Products were licensed in Georgia

Number of Registered Products 2015-2025*

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025*	Toplam
Produced Drugs	**8**	**1**	**18**	**2**	**9**	**17**	**30**	**24**	**18**	**16**	**4**	**147**
In Türkiye	6	1	7	0	2	1	4	6	0	3	3	33
Abroad	2	0	11	2	7	16	26	18	18	13	1	114
Exported Products	**1**	**21**	**0**	**0**	**5**	**3**	**0**	**13**	**1**	**4**	**11**	**59**
In Türkiye	1	16	0	0	5	0	0	4	1	4	10	41
Abroad	0	5	0	0	0	3	0	9	0	0	1	18
Total	**9**	**22**	**18**	**2**	**14**	**20**	**30**	**37**	**19**	**20**	**15**	**206**
In Türkiye	7	17	7	0	7	1	4	10	1	7	13	74
Abroad	2	5	11	2	7	19	26	27	18	13	2	132



These are the datas in the first 6 months of 2025

Rare Solutions For Rare Diseases

Solutions for Rare Diseases Like SMA, MS

With the partnerships made GEN ease access of patients to drugs for rare diseases within the scope of Named Patient Program (NPP). GEN has the leader position in this field.

Drug Research for NSCLC and other cancer types

Collaboration maintains with the RS Research which is research company established in Türkiye for the Non-Small Cell Lung Cancer and other cancer types.

Alzheimer and other neurodegenerative illnesses

Development of a new innovative drug for the Alzheimer and other neurodegenerative diseases with the collaboration made with Sulfateq B.V.

Strong Group

GENJECT
Sağlık Ürünleri Kimya Sanayi Ticaret A.Ş.

Genject, its own brand in Türkiye, manufactures single-use hypodermic syringes in accordance with CE standards.
GEN's shareholding rate in **GENJECT** is
96,40%

ELIXIR
İlaç Araştırma ve Geliştirme A.Ş.

GEN's shareholding rate in **Elixir,** which is integrated into the GEN Production Campus, is
95,00%

GEN Pharma Caucasus Manufacturing Operations MMC

GEN is a 66,00% shareholder of **Gen Pharma Caucasus,** which was established to establish a pharmaceutical production facility in Azerbaijan and to sell and market the products to be produced in this facility. Construction work of the facility is ongoing

Innovative Investments in Health Sector

RS RESEARCH

Jaguar Health

stimusil

h2o therapeutics

neOAUVRA SALUTOGENICS™

invios INNOVATIVE IMMUNO-ONCOLOGY

GALVENTA

Subsidiaries

SUBSIDIARIES	ACTIVITY AND ESTABLISHMENT PLACE	MAIN ACTIVITY	SHARE RATIO (%)
stimusil	USA	Medical Device Development	19,30
RS RESEARCH	**Türkiye**	Drug Research and Development	**11,70**
GALVENTA	Switzerland	Drug and Food Supplement Research and Development	4,55
neoAUVRA	**Türkiye**	**Biotechnological Medical Device Research and Development**	**35,15**
invios	Austria	Precision Cancer Immunotherapies	0,98
h2o therapeutics	**Türkiye**	**Digtal Health Technologies**	**10,00**
Jaguar Health	USA	Drug Research and Development	6,70

Business Partners (Türkiye)

Alnylam Pharmaceuticals
Amicus Therapeutics
Arna Pharma ...Enhancing Life
Bharat Biotech
BioMarin
Eisai
EUSA Pharma
Galventa
Guerbet
Helsinn
Incyte
IntraBio
Ipsen Innovation for patient care
Jaguar Health
Jazz Pharmaceuticals
moderna
Olpha
Onco Science
PTC Therapeutics
Recordati Rare Diseases
santhera Their future - our focus
Shuyang

Business Partners (Abroad)

Production Facility - Capacity

STERILE



Liquid Injecton Vial
26.520.000 vials/year



Lyophilized Injection Vial
5.300.000 vials/year

Cartridges
10.200.000 cartridges/year

Ready to Use Injection Syringes
2.040.000 syringes/year

Liquid Ampoules
45.900.000 ampoules/year

NON-STERILE



Tablet and Film Coated Tablets
400.000.000 tablets/year



Hard Gelatin Capsule
40.800.000 capsules/year



Sachet
14.688.000 sachets/year



Semi-solid
7.854.000 creams/year

Packaging
67.600.000 boxes/year

Sustainability

- **USD 7 - 8 mn** Solar Power Plant Investment
- **4,85 Mw** Installed Solar Power
- **11,85 Mw** installed capacity of the Solar Power Plant investment in Yozgat province

- **%56** Female Manager Rate
- **%46** Female Employee Rate

- **We Are Not Different, We Are Aware** - Employment of Individuals with Autism

17 PARTNERSHIPS FOR THE GOALS

- GEN is signatory of the World's biggest corporate sustainability initiative **United Nations Global Compact**
- Supporter of the 10 principles in the fields of Labor Standarts, Human Rights, Environment and Anti-Corruption **10 principles**

United Nations Global Compact

Production Facility

- **43.000 m2** Closed Area
- Europe, Türkiye, Russia, Kazakhstan, Philippines, Azerbaijan **GMP approved.**
- **1.200 m2** R&D Laboratory
- Republic of Türkiye Minister of Science, Industry and Technology **R&D Center Accreditation**

Stock Information

28.06.2024 Price → TL 65,29
30.06.2025 Price → TL 153,00
30.06.2025 Market Size TL → TL 45,90 Bn / USD 1,15 Bn





Innovative Projects

Project Name	SUL-238	GN-037	RS-139
Indication	**Alzheimer's and Neurodegenerative diseases**	**Psoriasis (Psoriasis Vulgaris)**	**Solid Cancers**
Stage	Phase 1 was completed	Phase 2 completed. Phase 3 will be launched in 2026	Phase 1b is ongoing.
The Probability of the Project Being Released, at this Stage (%)	15%	80%	4%
The Time Required for Commercialization Under the Best Case	6 yıl (2031 license application)	2 years (2028 license application)	8 years (2033 license application)
Estimated Number of Patients in Türkiye	An estimated 600 thousand patients in Türkiye.	An estimated 1.5 million patients in Türkiye.	It depends on Indication
2024 Türkiye Market Size $	USD 12 Mn	USD 150 Mn	It depends on Indication
2024 Global Market Size $	**USD 5,2 Bn**[1]	**USD 20 Bn**[2]	It depends on Indication
Project Completion Rate (%)	**55%**	**85%**	**45%**

Project Name	Amfoterisin B	Metoxalen
Indication	**Sistemik mantar enfeksiyonları**	**Sedef hastalığı (plak psoriasis)+PUVA**
Stage	Generic of the original Ambisome product.	Generic of the original Oxsoralen Ultra product.
The Probability of the Project Being Released, at this Stage (%)	95%	80%
The Time Required for Commercialization Under the Best Case	2 years (2027 license application)	3 years (2027 license application)
Estimated Number of Patients in Türkiye	It depends on Indication	An estimated 1.5 million patients in Türkiye.
2024 Türkiye Market Share Size $	USD 20 Mn	USD 150 Mn
2024 Global Market Share Size $	**USD 1.2 Bn**[3]	**USD 20 Bn**[4]
Project Completion Rate (%)	**95%**	**70%**

(1) https://www.towardshealthcare.com/insights/alzheimers-therapeutics-market-sizing
(2) https://www.globenewswire.com/news-release/2025/01/23/3014054/28124/en/Plaque-Psoriasis-Market-Research-2024-2034-Environmental-and-Genetic-Factors-Boost-Demand-Investments-in-Medical-R-D-Catalyze-Innovations.html
(3) https://dataintelo.com/report/global-liposomal-amphoteracin-b-market
(4) https://www.globenewswire.com/news-release/2025/01/23/3014054/28124/en/Plaque-Psoriasis-Market-Research-2024-2034-Environmental-and-Genetic-Factors-Boost-Demand-Investments-in-Medical-R-D-Catalyze-Innovations.html

Indecs


NATIONAL INDECS
BIST 500
BIST BUYBACK
BIST PARTICIPATION DIVIDEND
BIST ALL SHARES
BIST STARS
BIST ANKARA
BIST PARTICIPATION 100
BIST DIVIDEND
BIST 100-30
BIST 100
BIST SERVICES
BIST W. AND RETAIL TRADE
BIST PARTICIPATION ALL SHARES
INTERNATIONAL INDECS
FTSE World Europe Ex-England
MSCI Small Cap
FTSE All-World Ex-US

Summary Balance (TAS 29)

	30.06.2025	31.12.2024
ASSEST		
Current Assets		
Cash and Cash Equivalents	436.063.586	633.508.925
Financial Assets	104.501.691	107.951.716
Trade Receivables		
- Trade Receivables, Related Parties	*516.419.815*	*346.759.880*
- Trade Receivables, Third Parties	*1.779.507.386*	*1.562.347.838*
Other Receivables		
- Other Receivables, Related Parties	*1.564.577.048*	*680.442.710*
- Other Payables, Third Parties	*6.312.349*	*9.618.546*
Stocks	1.436.608.990	1.251.279.605
Prepaid Expenses	2.369.697.724	2.088.153.994
Current Tax-Related Assets	32.385.055	22.138.858
Other Current Assets	47.625.703	59.929.513
Total Current Assets	**8.293.699.347**	**6.762.131.585**
Non-Current Assets		
Financial Assets	963.693.588	821.240.891
Investment Properties	657.561.436	657.561.436
Intangible Non-Current Assets	4.785.040.724	4.803.482.479
Intangible Assets	1.208.736.676	1.124.085.009
Prepaid Expenses	329.462.550	173.893.278
Deferred Tax Assets	19.088.545	20.904.078
Total Non-Current Assets	**7.963.583.519**	**7.601.167.171**
Total Assets	**16.257.282.866**	**14.363.298.756**

	30.06.2025	31.12.2024
Short Term Liabilities		
Short Term Debts	1.140.570.895	462.633.571
Short Term Portion of Long-Term Financial Debts	367.236.649	369.281.268
Trade Payables		
- Trade Payables, Related Parties	*13.573.168*	*13.455.709*
- Trade Payables, Third Parties	*3.677.101.802*	*3.126.088.479*
Employee Benefit Obligations	87.975.721	25.366.110
Other Payables		
- Other Patables, Related Parties	*15.723.958*	*7.441.392*
- Other Payables, Third Parties	*36.196.634*	*22.800.727*
Deferred Incomes	940.967.198	824.146.249
Current Income Tax Liabiliteis	40.088.795	2.408.419
Short Term Provisions		
- Short Term Provisions for Employee Benefits	*55.225.977*	*30.499.338*
- Other Short Term Provisions	*15.625.364*	*9.616.381*
Total Short Term Liabilities	**6.390.286.161**	**4.893.737.643**
Long Term Liabilities		
Long Term Financial Liabilities	365.159.838	506.742.787
Trade Payables		
- Other Payables, Third Parties	*9.096.168*	*13.622.813*
Deferred Incomes	*25.996.877*	*307.181*
Long Term Provisions		
- Long Term Provisions for Employee Benefits	*100.297.935*	*87.774.088*
Deferred Tax Liabilities	443.153.827	334.970.658
Total Long Term Liabilities	**943.704.645**	**943.417.527**
Total Liabilities	**7.333.990.806**	**5.837.155.170**

Equities (TAS 29)

	30.06.2025	31.12.2024
EQUITIES		
Equity Attributable to Owners of the Parent		
Share Capital	300.000.000	300.000.000
Adjustment to Share Capital	1.851.732.852	1.851.732.852
Buyback Shares	-36.435.654	-36.421.781
Share Premiums/Discounts	2.634.360.825	2.634.360.825
Other Comprehensive Income/Expense not to be Reclassified to profit		
- Actuarial Loss / Gain	*-107.233.152*	*-91.155.764*
- Revaluation and Reclassification Gains	*1.418.088.764*	*1.418.126.844*
Comprehensive Income or Expenses		
- Foreign Currency Conversion Difference	*440.338*	238.837
Restricted Reserves Allocated from Profit	445.692.190	441.889.907
Prior Years Profit	2.002.011.607	1.832.285.276
Net Profit for the Period	**416.821.591**	**173.467.076**
Non Controlling Shares	-2.187.301	1.619.514
Total Equity	**8.923.292.060**	**8.526.143.586**
TOTAL ASSETS	**16.257.282.866**	**14.363.298.756**

Summary Income Statement (TAS 29)

	1 Jan – 30 June 25	1 Jan – 30 June 24	1 April – 30 June 25	1 April – 30 June 24
Revenue	8.378.744.586	8.798.229.535	4.289.020.443	4.260.743.498
Cost of Sales (-)	-6.607.146.418	-7.070.387.347	-3.395.289.509	-3.456.670.889
Gross Profit	**1.771.598.168**	**1.727.842.188**	**893.730.934**	**804.072.609**
General Administrative Expenses (-)	-348.962.995	-239.526.924	-140.742.145	-82.580.408
Marketing, Selling and Distribution Expenses (-)	-803.060.508	-680.217.337	-391.845.070	-334.404.080
Other Operating Income	-23.736.579	--	-23.736.579	--
Other Operating Expenses (-)	975.727.937	257.528.627	324.150.494	5.429.379
Revenue	-657.790.416	-294.407.744	-311.271.467	-73.880.092
Operating Profit	**913.775.607**	**771.218.810**	**350.286.167**	**318.637.408**
Income from Investing Activities	22.821.594	44.188.218	12.866.926	-11.470.234
Expenses from Investing Activities (-)	-10.250.182	-32.313.385	-1.874.890	-32.313.385
Operating Profit / (Loss) Before Financial Income	**926.347.019**	**783.093.643**	**361.278.203**	**274.853.789**
Financial Income	108.782.987	168.523.983	73.449.515	73.289.913
Financial Expenses (-)	-512.764.918	-484.226.682	-316.562.560	-226.712.121
Monetary Loss / Gain	35.497.697	-176.911.268	-44.019.538	-169.575.701
Profit Before Tax	**557.862.785**	**290.479.676**	**74.145.620**	**-48.144.120**
Tax Expense				
- Tax for the Period	-38.005.129	-1.137.761	-8.521.575	22.393.938
- Deferred Tax Income	-106.770.700	-298.384.615	12.129.496	-206.578.816
PROFIT FOR THE PERIOD	**413.086.956**	**-9.042.700**	**77.753.541**	**-232.328.998**
Profit for the period Attributable to				
Non Controlling Shares	-3.734.635	-697.185	-39.331	12.732.269
Equity Holders for the Parent	416.821.591	-8.345.515	77.792.872	-245.061.267
PROFIT FOR THE PERIOD	**413.086.956**	**-9.042.700**	**77.753.541**	**-232.328.998**
Earning Per Share	**1,38**	**-0,03**	**0,26**	**-0,77**

Investor Relations Communication

yatirimciiliskileri@genilac.com

https://www.genilac.com.tr/yatirimci-iliskileri-gen

Ali KETENCİOĞLU
Investor Relations Manager
P. +90 312 945 14 36 - ext: 528
M. +90 505 177 10 07
genilac.com.tr /gen_ilac
/genilac /genilactr

Can Onur DEMİRALP
Investor Relations Specialist
T. 0 312 945 14 36
C. 0 505 177 10 06
genilac.com.tr /gen_ilac
/genilac /genilactr

Disclaimer

All information presented in this presentation (presentation) has been prepared by Gen İlaç ve Sağlık Ürünleri Sanayi ve Ticaret A.Ş. (GENIL) in order to present information, projection and expressions about GENIL. The accuracy, adequacy and completeness of the information in this Presentation is not warrented. GENIL assumes no liability for any consequences arising from the use or content of this Presentation.

This Presentation is subject to change without notice, does not contain any investment advice or constitutes an offer or invitation to sell GENIL shares. This presentation and/or all information contained in the Presentation cannot be copied, disclosed distributed to any person unless shared or send by GENIL to relevant person.

All information in this presentation is top secret, the forward-looking statement contained in the Presentation is mentioned only as of the date of Presentation This presentation contains some forward-looking views and estimated figures. These reflect the current views of the Company Management regarding the future situation and include certain assumptions. However the realizations, may differ depending on the developments and realizations in the variables and assumptions that make up the forward-looking views and estimated figures. GENIL, or it employees, board of directors members, managers are not responsible from the losses arising from usage of the content of this Presentation.

Thank You.

For Healthier GENerations